# SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

> **NCT04913480** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 37 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** Stereotactic body radiation therapy

## Key facts

- **NCT ID:** NCT04913480
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2021-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04913480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04913480, "SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04913480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*